Keyword: Bayer

Bayer turns science into a verb with its new corporate campaign, “Why We Science"—the largest image push in the company's history.

Amid settlement talks, the number of Roundup lawsuits has more than doubled to 42,700, likely because of plaintiff-seeking TV ads, Bayer said.

While investors don't fancy megamergers, smaller deals in oncology could be the winning ticket, analysts have found.

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

Aurobindo and Glenmark are cited by the FDA. Takeda inks IBD discovery pact with Prometheus. Ascletis recruits Novartis veteran as CSO.

Pharma companies aren’t exactly blowing it on social media, but they’re also not taking full advantage of the platforms, a new report says.

Eli Lilly and Bayer are in the clear. A a court has tossed out “white-coat marketing” cases against the two pharmas.

Two C-level execs, including one who's under blame for an FDA warning letter, will leave Bayer first thing next year.

In terms of share value loss, Bayer's Monsanto deal stands among the worst corporate deals in modern history.